公开(公告)号：US10037874B2

公开(公告)日：2018-07-31

申请号：US14936847

申请日：2015-11-10

Applicant: Biodesix, Inc.

Inventor： Joanna Röder ,  Carlos Oliveira ,  Julia Grigorieva ,  Heinrich Röder ,  Devalingam Mahalingam

IPC: H01J49/00 ,  H01J49/16 ,  G01N33/574 ,  G01N33/68 ,  G06K9/62 ,  G16H50/70 ,  G16H10/40 ,  G06K9/00

CPC classification number: H01J49/0036 ,  G01N33/57438 ,  G01N33/6851 ,  G06K9/00147 ,  G06K9/00536 ,  G06K9/6228 ,  G06K9/6276 ,  G16H10/40 ,  G16H50/70 ,  H01J49/164 ,  Y02A90/26

Abstract: Hepatocellular carcinoma (HCC) is detected in a patient with liver disease. Mass spectrometry data from a blood-based sample from the patient is compared to a reference set of mass-spectrometry data from a multitude of other patients with liver disease, including patients with and without HCC, in a general purpose computer configured as a classifier. The classifier generates a class label, such as HCC or No HCC, for the test sample. A laboratory system for early detection of HCC in patients with liver disease is also disclosed. Alternative testing strategies using AFP measurement and a reference set for classification in the form of class-labeled mass spectral data from blood-based samples of lung cancer patients are also described, including multi-stage testing.

公开(公告)号：US10217620B2

公开(公告)日：2019-02-26

申请号：US16020183

申请日：2018-06-27

Applicant: Biodesix, Inc.

Inventor： Joanna Röder ,  Carlos Oliveira ,  Julia Grigorieva ,  Heinrich Röder ,  Devalingam Mahalingam

IPC: H01J49/00 ,  G06K9/62 ,  G01N33/574 ,  G01N33/68 ,  H01J49/16 ,  G16H10/40 ,  G16H50/70 ,  G06K9/00

Abstract: Hepatocellular carcinoma (HCC) is detected in a patient with liver disease. Mass spectrometry data from a blood-based sample from the patient is compared to a reference set of mass-spectrometry data from a multitude of other patients with liver disease, including patients with and without HCC, in a general purpose computer configured as a classifier. The classifier generates a class label, such as HCC or No HCC, for the test sample. A laboratory system for early detection of HCC in patients with liver disease is also disclosed. Alternative testing strategies using AFP measurement and a reference set for classification in the form of class-labeled mass spectral data from blood-based samples of lung cancer patients are also described, including multi-stage testing.

公开(公告)号：US20160163522A1

公开(公告)日：2016-06-09

申请号：US14936847

申请日：2015-11-10

Applicant: Biodesix, Inc.

Inventor： Joanna Röder ,  Carlos Oliveira ,  Julia Grigorieva ,  Heinrich Röder ,  Devalingam Mahalingam

IPC: H01J49/00 ,  H01J49/16

CPC classification number: H01J49/0036 ,  G01N33/57438 ,  G01N33/6851 ,  G06F19/00 ,  G06K9/00147 ,  G06K9/00536 ,  G06K9/6228 ,  G06K9/6276 ,  G16H10/40 ,  G16H50/70 ,  H01J49/164 ,  Y02A90/26

Abstract: Hepatocellular carcinoma (HCC) is detected in a patient with liver disease. Mass spectrometry data from a blood-based sample from the patient is compared to a reference set of mass-spectrometry data from a multitude of other patients with liver disease, including patients with and without HCC, in a general purpose computer configured as a classifier. The classifier generates a class label, such as HCC or No HCC, for the test sample. A laboratory system for early detection of HCC in patients with liver disease is also disclosed. Alternative testing strategies using AFP measurement and a reference set for classification in the form of class-labeled mass spectral data from blood-based samples of lung cancer patients are also described, including multi-stage testing.

Abstract translation: 在肝病患者中检测到肝细胞癌（HCC）。 将来自患者的血液样品的质谱数据与来自多个其他肝病患者的质谱数据进行比较，所述其他患者包括具有和不具有HCC的患者，在配置为分类器的通用计算机中。 分类器为测试样本生成类标签，如HCC或No HCC。 还公开了一种用于肝病患者中HCC早期检测的实验室系统。 还描述了使用AFP测量和来自肺癌患者血液样品的类别标记质谱数据形式的分类参考文献的替代测试策略，包括多阶段测试。